RxDoctor Payments Data

Negin Kourehpazan Haghighi

Gerontology · Bellevue, WANPI 1457011967

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 29.4% of the total.

$955in general payments, 2019–2025

Across 43 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$280
  • Novo Nordisk$189
  • Bayer$92
  • Takeda Pharmaceuticals U.S.A., Inc.$82
  • Vanda Pharmaceuticals Inc.$81
  • Phadia US Inc.$73
  • plus $158 from 5 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 75th percentile of 105 gerontology providers in Washington.

See all gerontology providers in Washington

Medicare billing

Part B allowed, 2024
$34,155
Medicare patients
167
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$31,429
OzempicSemaglutide20$28,850
EliquisApixaban15$11,897
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,074
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,970
Atorvastatin Calcium124$1,286
Omeprazole59$1,080
Albuterol Sulfate HfaAlbuterol Sulfate29$1,034
Fluticasone Propionate14$810
Nifedipine ErNifedipine13$644
Gabapentin32$603
Morphine Sulfate ErMorphine Sulfate21$590
Lisinopril61$550
Tamsulosin Hcl21$514
Rosuvastatin Calcium31$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$189$28,85020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 gerontology providers in Washington.

Other gerontology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →